Anti-Hypertensive Drugs - Malawi

Malawi

The projected revenue in Malawi's Anti-Hypertensive Drugs market is expected to reach US$1.62m in 2024.
It is anticipated that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of -0.75%, leading to a market volume of US$1.56m by 2029.
In comparison to other countries worldwide, United States is projected to generate the highest revenue of US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Malawi is steadily increasing due to a rising prevalence of hypertension among the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Malawi has been experiencing steady growth in recent years.

Customer preferences: Patients in Malawi prefer generic drugs due to their affordability. This has led to an increase in demand for generic anti-hypertensive drugs. However, there is also a growing demand for branded drugs among the middle and upper-class population who are willing to pay a premium for better quality drugs.

Trends in the market: The government of Malawi has been making efforts to improve access to healthcare services in the country. This has led to an increase in the number of people seeking medical attention, including treatment for hypertension. As a result, the demand for anti-hypertensive drugs has been on the rise.

Local special circumstances: Malawi has a high prevalence of hypertension, with over 25% of the adult population suffering from the condition. This has led to an increased demand for anti-hypertensive drugs in the country. In addition, the country has a shortage of healthcare professionals, which has led to patients relying on self-medication. This has also contributed to the demand for anti-hypertensive drugs.

Underlying macroeconomic factors: The Malawian economy has been growing steadily in recent years, with a focus on agriculture and mining. This has led to an increase in disposable income among the population, which has contributed to the demand for branded drugs. However, the majority of the population still lives below the poverty line, and affordability remains a key factor in the choice of drugs. The government has been making efforts to improve access to healthcare services in the country, which has also contributed to the growth of the anti-hypertensive drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.